Halozyme CEO Sells $635,000 in Shares

Helen Torley reduces stake by 1.29% through pre-arranged trading plan

Apr. 7, 2026 at 10:10pm

Got story updates? Submit your updates here. ›

A dramatic, high-contrast close-up of intricate, metallic banking mechanisms and components, conveying a sense of institutional power and financial security without using any literal currency or charts.An insider stock sale by Halozyme's CEO highlights the complex machinery behind the biopharmaceutical industry's financial transactions.San Diego Today

Halozyme Therapeutics CEO Helen Torley sold 10,000 shares of the company's stock on Monday, April 6th, for a total transaction value of $635,000. The sale represented a 1.29% decrease in Torley's ownership stake, which now stands at 767,780 shares valued at $48.75 million.

Why it matters

Insider stock sales can provide insight into executive sentiment and confidence in a company's future prospects. Torley's sale, executed under a pre-arranged trading plan, suggests she may see limited near-term upside in Halozyme's share price despite the company's recent strong financial performance.

The details

The stock was sold at an average price of $63.50 per share. Following the transaction, Torley directly owns 767,780 shares in the company. This marks the latest in a series of stock sales by Torley, who has divested a total of 80,000 Halozyme shares since the beginning of 2026 for over $5 million in proceeds.

  • The shares were sold on Monday, April 6, 2026.
  • Torley has made multiple stock sales since the start of 2026, totaling 80,000 shares.

The players

Helen Torley

CEO of Halozyme Therapeutics, Inc., a biopharmaceutical company focused on drug delivery technologies.

Halozyme Therapeutics, Inc.

A NASDAQ-listed biopharmaceutical company that specializes in the development and commercialization of novel drug-delivery technologies.

Got photos? Submit your photos here. ›

The takeaway

Torley's stock sale, while not unexpected given Halozyme's recent share price appreciation, may raise questions about the company's near-term growth prospects among some investors. However, the transaction was pre-planned, and Torley still maintains a significant ownership stake, suggesting continued confidence in Halozyme's long-term potential.